Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GABRP | O00591 | 5/20 | 0.49 |
| ▸ | GABRD | O14764 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971939 | 1.00 | MAPK1 (0.61) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL7356681 | 0.92 | MAPK1 (0.75) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL370722 | 0.90 | P4HTM (0.59) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL16998556 | 0.90 | MAPK1 (0.53) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL2585062 | 0.90 | KDM4E (0.68) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL11386893 | 0.88 | MAPK1 (0.51) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL2963596 | 0.88 | KDM4E (0.66) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL4778427 | 0.88 | MAPK1 (0.51) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL2109944 | 0.87 | MAPK1 (0.50) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL2412458 | 0.87 | MAPK1 (0.50) | MAPK1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322350-A | Degradable bio-based polyester and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114585605-B | Pharmaceutical compounds | 圣提内尔肿瘤学有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119350236-A | Synthesis method of 3-chloro-5-cyano-2-picolinic acid and derivative thereof | 帕潘纳(北京)科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-115322350-B | Degradable bio-based polyester and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-110573503-B | Pyrrole derivatives as PLK1 inhibitors | 圣提内尔肿瘤学有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115322350-A | Degradable bio-based polyester and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220348565-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-11-03 | — | — | US | disclosed |
| CN-113429410-B | Polyheterocyclic substituted pyrimidine or pyridylamine derivatives, compositions and medical uses thereof | 上海海雁医药科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4034246-A1 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2022-08-03 | — | — | EP | disclosed |
| CN-114585605-A | Pharmaceutical compounds | 圣提内尔肿瘤学有限公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348565-A1 | PHARMACEUTICAL COMPOUNDS | PLK1, PLK4, PLK2 | MAPK1 529/4885CA12 4387/4885CA1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.